Stock Market Today, October 20, 2026: Dow Gains 530 Points, Small Caps Lead as Housing Weakens -( $AMWL $BRZE $CRM $DOCS $EPRX $GM $LLY $MODD $NOC $NVDA $SER $SPCX $TSLA $WMT )

U.S. stocks finished Tuesday with a split performance as the Dow Jones Industrial Average gained 529.85 points, the S&P 500 advanced modestly and the Nasdaq Composite slipped just below unchanged. Small-cap stocks led the major benchmarks, with the Russell 2000 rising 1.65%, while the Cboe Volatility Index declined 5.42%. The session’s defining theme was breadth: investors found opportunities beyond the largest technology companies as corporate earnings and easing oil prices supported buying. However, a disappointing batch of housing reports underscored the economy’s sensitivity to high borrowing costs, and the Federal Reserve’s difficult balance between containing inflation and protecting growth.

Stock Market Closing Performance: October 20, 2026

The Russell 2000 outperformed the S&P 500 by 1.37 percentage points, illustrating the day’s stronger appetite for smaller companies. The contrast between the Dow’s advance and the Nasdaq’s slight decline also showed that Tuesday’s gains did not depend on a broad surge in technology shares.

Why Stocks Rose: Earnings Support and Lower Oil Prices

Corporate results helped investors look past renewed concerns about artificial intelligence spending. During the session, approximately three-quarters of S&P 500 constituents were trading higher, according to Yahoo Finance’s market coverage. Healthcare, airlines and homebuilders participated as oil prices retreated from earlier levels. That was an intraday breadth reading, not a final advance-decline count. Industrial and defense earnings provided additional support. 3M (NYSE: MMM) reported adjusted earnings of $2.50 per share, exceeding the $2.38 consensus estimate cited by CNBC, and raised its full-year guidance. Northrop Grumman (NYSE: NOC) posted earnings of $7.89 per share against expectations of $7.18, although revenue of $11.12 billion came in slightly below forecasts. Both stocks advanced during the session. Healthcare also helped broaden participation. Eli Lilly (NYSE: LLY), UnitedHealth Group (NYSE: UNH) and Merck (NYSE: MRK) were among the companies highlighted in the sector’s intraday advance. Meanwhile, several heavyweight technology stocks lagged, limiting the broader indexes’ progress. The distinction matters: a rising market supported by more industries has a different leadership profile from one driven primarily by a handful of megacap technology companies. Tuesday’s index results were consistent with that broader participation, even though the Nasdaq finished marginally lower.

Macroeconomic Report: Housing Weakness Complicates the Fed Outlook

Housing delivered the day’s clearest economic warning. September construction and contract-signing activity weakened as elevated mortgage rates continued to constrain affordability.

Figures reported by CNBC from Commerce Department and National Association of Realtors releases. Annualized construction figures represent seasonally adjusted yearly rates, not the number of homes built during September alone.

Why weaker housing does not automatically mean lower interest rates

The central problem is that housing weakness is arriving alongside persistent inflation pressure. CNBC reported mortgage rates around 7.43%, following readings near 7.6% at the end of September. Such borrowing costs discourage purchases while making homeowners reluctant to surrender existing, lower-rate mortgages. That creates a two-sided constraint: prospective buyers struggle with affordability, while existing owners have less incentive to list their homes. Consequently, weak transaction activity can coexist with limited supply rather than quickly producing a more affordable market. Ordinarily, a weakening interest-rate-sensitive sector could strengthen the argument for easier monetary policy. But inflation complicates that response. CNBC reported that market pricing favored an unchanged Fed benchmark rate at the next meeting while assigning a strong chance of quarter-point increases in December and March 2027. Those expectations remain market estimates, not announced policy decisions. For investors, the implication is a difficult mix: softer housing points to pressure on growth, but it does not by itself establish that inflation has cooled enough for monetary relief.

Corporate News: Earnings, AI Investment and Software Consolidation

General Motors tops estimates and authorizes a $20 billion buyback

General Motors (NYSE: GM) reported third-quarter revenue of $50.0 billion, exceeding the $48.52 billion consensus cited by Yahoo Finance. Adjusted earnings reached $3.70 per share versus expectations of $3.57, while adjusted operating earnings totaled $4.1 billion. The automaker also announced a new $20 billion share-repurchase authorization and narrowed its full-year profit outlook. Nevertheless, shares were under pressure before the opening bell. The reaction highlighted how guidance and inflation exposure can outweigh a headline earnings beat; the reported premarket decline should not be confused with a verified closing return.

Salesforce agrees to acquire Braze for $5.66 billion

Salesforce (NYSE: CRM) announced an agreement to acquire customer-engagement software company Braze (NASDAQ: BRZE) for approximately $5.66 billion. Under the announced terms, Braze Class A shareholders would receive $47.50 in cash per share, with closing expected in Salesforce’s fiscal 2028. Braze shares jumped more than 50% in early trading, while Salesforce shares slipped. Strategically, the proposed transaction would add customer-data and AI-enabled marketing capabilities to Salesforce’s platform. The acquisition remains pending rather than completed.

AI infrastructure concerns remain beneath the rebound

The broader rally did not eliminate questions about financing the AI buildout. CNBC reported that credit-protection costs on CoreWeave (NASDAQ: CRWV) remained elevated, even as its shares recovered during the session. Yahoo Finance also highlighted investor concern about leverage and the durability of demand across AI infrastructure businesses. The important distinction is between demand for computing capacity and the returns earned on the capital required to supply it. A recovery in AI-related stocks does not necessarily mean debt-market concerns have disappeared.

SpaceX earnings preview puts spending and monetization in focus

Ahead of its scheduled after-the-bell report, SpaceX (NASDAQ: SPCX) faced analyst expectations of $12.72 billion in revenue and earnings of $0.13 per share, according to the consensus figures cited by CNBC. After the bell, SpaceX reported 161% revenue growth for the third quarter, beating Wall Street estimates, as the company’s artificial intelligence business grew ninefold. The stock rose about 1.5% in extended trading on Tuesday. Revenue: $14.58 billion vs. $12.72 billion expected & Earnings per share: 35 cents.

Tesla and Walmart: Long-Term Growth Expectations Meet Consumer Value

Cathie Wood’s Tesla forecast is a multiyear scenario

Tesla (NASDAQ: TSLA) attracted attention after ARK Invest outlined a $4,400 base-case share-price target for 2031, alongside a $5,000 bull case and a $3,300 bear case. Yahoo Finance reported that the projections reflect optimistic assumptions about robotaxis, humanoid robots and Terrafab. The time horizon is essential. These are long-term investment scenarios—not near-term price objectives, company guidance or guaranteed outcomes. Separately, investors were preparing for Tesla’s scheduled Wednesday earnings report, with profitability and cash flow among the central issues.

Walmart combines memberships for $120 annually

Walmart (NASDAQ: WMT) launched a $120 annual package combining Walmart+ with Sam’s Club Plus. The company said the bundle costs nearly $100 less than purchasing the two memberships separately. The offer connects directly to the affordability backdrop: Walmart is using convenience, delivery and membership value to compete for consumer spending. Strategically, the bundle gives the retailer another way to deepen customer relationships while households navigate elevated living costs.

Bonds, Oil, Gold, Bitcoin and Volatility

Lower oil and Treasury yields provided a more supportive backdrop during the session, while the decline in the volatility index accompanied the broader equity advance. Nevertheless, a 10-year yield above 5% remained an important part of the valuation and borrowing-cost environment.

What Many Are Watching Next

• Earnings follow-through: Whether upcoming results support profit expectations after Tuesday’s gains outside megacap technology.
• AI financing: Whether operating growth can justify heavy infrastructure spending and reassure debt investors.
• Housing and inflation: Whether weakening construction and home sales change the policy outlook, or remain secondary to inflation concerns.
• Market leadership: Whether small caps and nontechnology sectors can sustain their relative strength beyond a single session.

Here’s The VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $13.20, +7.06%.

AMWL announced (Sept 8) announced the Department of Veterans Affairs (VA) has declared its intent for the Company to deploy its virtual health platform within the VA enterprise and help power the modernization of the VA’s digital health infrastructure. The VA anticipates the Amwell platform will support a broad range of clinical services, enhance care coordination, and improve access for our Veterans across the VA enterprise. The Letter of Intent follows a comprehensive evaluation process by the VA, in which it determined that Amwell’s virtual health platform aligns with the Department’s strategic objectives to expand access to high-quality, secure, and reliable virtual care services for Veterans nationwide through the VA’s current electronic health record modernization efforts. Specifically, the capabilities Amwell demonstrated in scalable video consultations, interoperability, cybersecurity compliance, and support for integrated care delivery were significant factors in this determination.

Amwell® has received Frost & Sullivan’s 2026 United States Technology Innovation Leadership Recognition in the Technology-Enabled Care Platforms Industry. The recognition validates Amwell’s ability to address healthcare fragmentation through a unified platform that orchestrates consumer experiences, clinician workflows, care programs, and partner solutions.

The Company also reiterated recently its objective to achieve positive cash flow from operations in the fourth quarter of 2026.

Serina Therapeutics (NYSE: SER)

Serina Theraeuptics (NYSE: SER, $1.66, +.61%) is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

On Thursday, September 24, 2026, Serina CEO Steve Ledger discussed discuss Serina’s programs’ progress during Tribe Public’s “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress”webinar, followed by a live Q&A. You may view it below.

SER announced (Sept. 9) that the independent Safety Monitoring Committee (SMC) has completed its blinded review of Cohort 1 of the ongoing Phase 1b registrational study of SER-252 in patients with advanced Parkinson’s disease and recommended that the study advance to Cohort 2. Cohort 1 evaluated the lowest dose level in the single-ascending-dose portion of the study. In addition to supporting continued dose escalation, blinded Cohort 1 observations showed a pharmacokinetic profile consistent with the sustained apomorphine exposure SER-252 is designed to provide and included sustained periods of improvement in motor function in individual patients on exploratory clinical measures.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $7.59, +9.21%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (Oct. 15) that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached its enrollment target. “This is a significant milestone for the RESOLVE trial and the development of EP-104GI as a potential treatment option in EoE” said Dr. James Helliwell, Chief Executive Officer of Eupraxia. “We look forward to our interim analysis in December where we will be reporting on symptoms, histologic findings and safety in the first 60 patients in Phase 2b to reach 6 months. Data will also be available on the patients at 3, 9- and 12-month timepoints giving a fulsome interim look at the RESOLVE Trial”.

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $1.95), a commercial-stage medical device company preparing for the full commercial launch of its next-generation Pivot™ tubeless patch pump, announced (October 15) the launch of two innovative digital education resources designed to assist people living with diabetes build familiarity and confidence with insulin therapy ahead of formal training on the Pivot insulin delivery system. Developed in partnership with Relevate Health Games, the new tools use game-based technology to walk patients through the skills needed for insulin pump therapy. The resources are designed to help reduce barriers to adoption by allowing prospective users to become familiar with pump therapy before beginning formal onboarding. The first educational module gives users a virtual, hands-on walkthrough of the Pivot insulin delivery system. In approximately 15 minutes, users can visualize how to unpack the system, prepare and apply the pump, and understand the basic operational functions. The Pivot module was first previewed at the ADCES 2025 Annual Conference in August 2025. Healthcare providers may also use the platform to gauge a patient’s interest in pump therapy and ability to navigate basic operational tasks associated with insulin delivery devices. The experience offers clinicians valuable insight into patient engagement, learning readiness, and willingness to transition from multiple daily injections to a more advanced insulin delivery approach.

MODD announced (September 4) that it has secured a contract with a national U.S. pharmacy benefit manager (PBM) in the United States. Pursuant to the contract, the Company’s Pivot insulin delivery system is now available through the national PBM. The Company believes the engagement with this national PBM represents a significant step forward in broadening patient access to the Company’s Pivot tubeless patch pump and will further validate the Pivot pump as an accessible therapeutic option for people living with diabetes.

MODD announced (September 3) that the U.S. Food & Drug Administration (FDA) has cleared a set of software enhancements to its Pivot insulin delivery system, further expanding the system’s functionality and providing users with greater flexibility and customization options in bolus dosing, an enhanced user-interface (UI), and other software upgrades.

MODD CEO, Jeb Besser, co-hosted a Tribe Public’s CEO Presentation and Q&A Webinar Event titled “The Road To Revenue: Modular Medical’s Strategy For Launching Pivot,” that was held Friday, September 4, 2026.. You may watch the event video below now if you missed it below now.

Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE: DOCS, $33.35, +6.04%) is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.

Doximity and Wolters Kluwer Health, announced (Oct. 20) that UpToDate’s trusted, evidence-based, clinical content will be accessible directly within Doximity’s fast-growing AI clinical decision support tool, Ask.

DOCS announced (Oct. 13) it has extended its 13-year partnership with U.S. News & World Report, the nation’s most trusted source of independent healthcare information, rankings and guidance to help patients identify the best care for their needs.

Nvidia (NVDA, $216.47, -.29%)

NVIDIA Corp. (NASDAQ: NVDA). AM Intelligence (“AMI”), the AI infrastructure platform set up by Promoters of Greenko, announced (Oct. 5) two further firm and binding orders for 20,000 NVIDIA Rubin GPUs, to be deployed as NVIDIA Vera Rubin NVL72 rack-scale systems. Building on its first AI factory in Hyderabad, the expansion is designed to give cloud providers, enterprises and AI developers access to large-scale computing capacity closer to where they build and deploy AI.

NVDA recently has seemingly has given many a two-part bullish signal: a record-sized $150 billion increase to its share-repurchase authorization and a new AI-agent safety platform aimed at making autonomous software more secure for enterprise deployment. The combination suggests a company using extraordinary financial strength not merely to reward shareholders, but to expand its influence from AI computing into the governance, security and operating layer of the AI economy. The timing is notable. Markets are beginning the week with a cautiously constructive tone, even as investors brace for jobs, inflation and manufacturing data that could reset the outlook for interest rates. In that environment, NVIDIA is making a familiar but potent argument: its AI franchise is generating enough cash to finance innovation, deepen its ecosystem and return meaningful capital to shareholders, all at once. That is not an everyday corporate trick. It is closer to juggling bowling balls while also building the bowling alley.

The Sources

1. Yahoo Finance: Stock market today: Dow rises, S&P 500, Nasdaq climb as oil prices ease, chip stocks trim losses
2. CNBC: Stock market live updates: Earnings and falling crude oil support a rebound
3. CNBC: Housing is flashing warning signs just as the Fed weighs more interest rate hikes
4. CNBC: Salesforce announces $5.66 billion deal for Braze
5. CNBC: SpaceX earnings live updates: Analyst expectations ahead of the report
6. Yahoo Finance: Why Tesla bull Cathie Wood thinks the stock is headed to $5,000
7. Walmart: Meet Your $120 Life Hack: Walmart+ and Sam’s Club Plus, Together
8. Reuters: Walmart launches $120 membership bundle with Sam’s Club ahead of holidays
9. CNBC: Walmart launches Walmart+, Sam’s Club Plus joint membership